26 May 2022 (Thursday) - Transfusion News Update

The nice people at “Transfusion News” sent their update today. Perhaps not as useful as some of their output… but all good stuff.

Genomic Profiles Associated with CAR T-Cell Therapy Efficacy

May 24, 2022Chimeric antigen receptor (CAR) T-cell therapy is a promising therapy used to treat hematological cancers by targeting a specific antigen. Notably, CD19 CAR T-cell therapy has a 90% complete response rate in children and adults with acute lymphoblastic leukemia (ALL), but it is unclear why about 10% of patients do not respond to treatment. [Read More]


New perspectives in Transfusion Medicine in Spanish Speaking Countries

Join Transfusion News Associate Editors Daniela Hermelin MD and Monica Pagano MD on Friday May 27 from 11:00-11:30 AM EST for the next #Blooducation Baristas live event. Dr. Heremlin and Dr. Pagano will be joined by Dr. José Arnulfo Pérez-Carrillo, Dra. Silvina Kuperman and Dr. Hector Baptista for our first event en español. [Set a reminder to join us]


Risk Factors for Allergic Transfusion Reactions in Pediatric Patients

May 17, 2022 Allergic transfusion reactions (ATRs) are common and can range from mild to severe. Younger age, hematological/oncological disease, increasing number of transfusions, and past history of ATRs are all risk factors for ATRs. Although the exact mechanism for ATRs is not well understood, type I immunoglobulin E (IgE)-mediated hypersensitivity and/or basophils are likely involved. [Read More]

No comments:

Post a Comment